US 12,486,281 B2
Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
Frans Baculi, San Diego, CA (US); Katherine Northcote, San Diego, CA (US); Matthew D. Correa, San Diego, CA (US); Joshua Hansen, La Jolla, CA (US); Laurie A. Lebrun, San Diego, CA (US); Chin-Chun Lu, San Diego, CA (US); Gang Lu, San Diego, CA (US); Mark A. Nagy, San Diego, CA (US); Sophie Peng, San Diego, CA (US); and Sophie Perrin-Ninkovic, La Jolla, CA (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US)
Filed on Mar. 9, 2022, as Appl. No. 17/690,921.
Application 17/690,921 is a continuation of application No. 16/887,766, filed on May 29, 2020, granted, now 11,306,101.
Claims priority of provisional application 62/855,619, filed on May 31, 2019.
Prior Publication US 2022/0213115 A1, Jul. 7, 2022
Int. Cl. C07D 491/107 (2006.01); A61P 35/02 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01)
CPC C07D 491/107 (2013.01) [A61P 35/02 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01)] 25 Claims
 
1. A process for preparing a compound of Formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, tautomer, isotopolog, or stereoisomer thereof, comprising contacting a compound of formula b

OG Complex Work Unit Chemistry
wherein X is OH, with NH2(CR1R2R3), in a solvent, in the presence of a coupling agent and a base, wherein
R1 is C1-3 alkyl, or C1-3 fluoroalkyl;
R2 is substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C3-10 cycloalkyl, substituted or unsubstituted 3-6-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, or substituted or unsubstituted 5-10-membered heteroaryl;
R3 is H;
R4 is halogen; and
n is 0-3.